Sensei biotherapeutics reports first quarter 2023 financial results and recent business highlights

- investigational new drug (ind) application for sns-101 cleared by u.s. food and drug administration (fda) with first patient dose in phase 1/2 trial expected in mid-2023 -

SNSE Ratings Summary

SNSE Quant Ranking